In January 2018, Biogen dosed the first patient in the Phase 2 SPARK study of BIIB054 (anti-alpha-synuclein antibody) in Parkinson's disease.
The University of Zurich conducts world-class research and has achieved international renown in the fields of medicine, immunology, neuroscience and structural biology. It is one of the Leading Houses in six National Centers of Competence in Research, with three projects in the field of life sciences, one specifically focusing on neuroscience. Over the years, the Nobel Prize has been conferred upon twelve UZH scholars, including Wilhelm Conrad Röntgen, the recipient of the first Nobel Prize in Physics. As one of the major focus areas at the University of Zurich, neuroscience research is performed in associations with national and international institutions, and with ETH Zurich. Neurimmune maintains a strong and highly productive partnership with the University of Zurich, especially with its world-renowned center for neuroscience.